25. Progressive multifocal leukoencephalopathy
[
16 clinical trials,
26 drugs（DrugBank:
20 drugs),
7 target genes / 34 target pathways ]
Searched query = "Progressive multifocal leukoencephalopathy", "Leukoencephalopathy, progressive multifocal"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04091932 | August 20, 2019 | 30 September 2019 | Treatment of PD-1 Inhibitor in AIDS-associated PML | The Effect and Safety of Programmed Cell Death Protein 1 (PD-1) Inhibitor on AIDS Patients With Progressive Multifocal Leukoencephalopathy (PML): A One-center, Single-arm and Prospective Study | Progressive Multifocal Leukoencephalopathy;AIDS | Drug: Pembrolizumab | First Affiliated Hospital of Zhejiang University | Recruiting | 18 Years | 65 Years | All | 10 | Phase 2 | China | |
| 2 | NCT03399981 | January 24, 2018 | 24 June 2019 | Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries | An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With Tysabri | Progressive Multifocal Leukoencephalopathy | Biological: Tysabri | Biogen | Not recruiting | N/A | N/A | All | 72600 | N/A | United States | |
| 3 | JPRN-UMIN000022151 | 2016/04/30 | 2 April 2019 | The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy | The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy | mefloquine is to be taken orally 275mg for 3days then 275mg weekly for 6 manths | Department of Neurology, Shimane University Hospital | Recruiting | 20years-old | Not applicable | Male and Female | 5 | Not selected | Japan | ||
| 4 | JPRN-UMIN000023752 | 2016/04/14 | 2 April 2019 | Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance | progressive multifocal leukoencephalopathy | Oral mefloquine hydrochloride 275mg once a day at first 3 days. Since second week, 275mg in each week oral intake until 6 months | Nagoya City University | Not Recruiting | Not applicable | Not applicable | Male and Female | 1 | Not applicable | Japan | ||
| 5 | NCT02694783 | March 28, 2016 | 11 March 2019 | Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells | A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-cells | Leukoencephalopathy | Biological: PyVST;Other: No Intervention | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | N/A | All | 60 | Early Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT01970410 | October 2013 | 11 June 2018 | Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide | Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective? | Multiple Sclerosis | Drug: teriflunomide | Multiple Sclerosis Center of Northeastern New York | Providence Multiple Sclerosis Center | Not recruiting | 21 Years | 60 Years | All | 70 | Phase 4 | United States |
| 7 | EUCTR2012-000725-41-GB | 22/01/2013 | 10 March 2014 | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy. - INVICTUS | HIV-infected patients with Progressive Multifocal Leukoencephalopathy MedDRA version: 15.0 Level: PT Classification code 10036807 Term: Progressive multifocal leukoencephalopathy System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02] | Product Name: Recombinant human interleukin-7 Product Code: CYT107 Pharmaceutical Form: Solution for injection INN or Proposed INN: N/A CAS Number: N/A Current Sponsor code: CYT107 Other descriptive name: Recombinant human interleukin-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Cytheris S.A. | Not Recruiting | Female: yes Male: yes | 57 | Phase 2b | United States;European Union;Spain;Italy;Switzerland;United Kingdom | |||
| 8 | NCT01211665 | September 2010 | 19 October 2017 | Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) | High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab | Immune Reconstitution Inflammatory Syndrome;Leukoencephalopathy, Progressive Multifocal | Drug: Methylprednisolone;Drug: Prednisolone | Biogen | Elan Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 3 | Phase 4 | United States;Germany |
| 9 | EUCTR2008-001314-24-GB | 02/01/2009 | 19 March 2012 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) | Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1 Level: LLT Classification code 10036807 Term: Progressive multifocal leukoencephalopathy | Trade Name: Lariam Product Name: Mefloquine Product Code: 111JC101 Pharmaceutical Form: Tablet INN or Proposed INN: MEFLOQUINE CAS Number: 53230107 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- | Biogen Idec Ltd | Not Recruiting | Female: yes Male: yes | 60 | United Kingdom;France;Spain;Italy | ||||
| 10 | NCT00746941 | January 2009 | 19 October 2017 | Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML) | Progressive Multifocal Leukoencephalopathy | Drug: mefloquine | Biogen | Elan Pharmaceuticals | Not recruiting | 18 Years | 75 Years | All | 37 | Phase 1/Phase 2 | United States;Brazil;Germany;Italy;Spain;Australia;France;Puerto Rico;United Kingdom |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT00120367 | April 2005 | 19 February 2015 | Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125) | Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 Trial | Leukoencephalopathy, Progressive Multifocal;HIV Infections | Drug: Enfuvirtide;Drug: Tenofovir-Emtricitabine | French National Agency for Research on AIDS and Viral Hepatitis | Hoffmann-La Roche;Gilead Sciences | Not recruiting | 18 Years | N/A | Both | 30 | Phase 2 | France |
| 12 | NCT00000945 | November 1999 | 19 February 2015 | A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients | A Pilot Study of the Effect of Cidofovir for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Subjects With Acquired Immunodeficiency Syndrome (AIDS) | HIV Infections;Leukoencephalopathy, Progressive Multifocal | Drug: Cidofovir;Drug: Probenecid | National Institute of Allergy and Infectious Diseases (NIAID) | Not recruiting | 18 Years | N/A | Both | 24 | N/A | United States | |
| 13 | NCT00001048 | February 1998 | 19 February 2015 | Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients | A Phase II Multicenter Study Comparing Antiretroviral Therapy Alone to Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Human Immunodeficiency Virus (HIV)-Infected Subjects | HIV Infections;Leukoencephalopathy, Progressive Multifocal | Drug: Filgrastim;Drug: Cytarabine;Drug: Zidovudine;Drug: Zalcitabine;Drug: Didanosine | National Institute of Allergy and Infectious Diseases (NIAID) | Bristol-Myers Squibb;Upjohn | Not recruiting | 18 Years | 65 Years | Both | 90 | Phase 2 | United States |
| 14 | NCT00002270 | October 1997 | 19 February 2015 | A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection | A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection | HIV Infections;Leukoencephalopathy, Progressive Multifocal | Drug: Interferon alfa-2b;Drug: Zidovudine | University of Miami | Not recruiting | 18 Years | 65 Years | Both | N/A | United States | ||
| 15 | NCT00002274 | October 1997 | 19 February 2015 | A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine | An Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) Exhibiting Significant Deterioration While Taking Zidovudine (Retrovir) | HIV Infections;Leukoencephalopathy, Progressive Multifocal | Drug: Didanosine | Bristol-Myers Squibb | Not recruiting | 12 Years | N/A | Both | N/A | United States | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT00002395 | June 1996 | 19 February 2015 | Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML) | An Open, Comparative Phase II Study of Immediate Versus Delayed Treatment With Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy | HIV Infections;Leukoencephalopathy, Progressive Multifocal | Drug: Topotecan | SmithKline Beecham | Not recruiting | 18 Years | N/A | Both | 54 | Phase 2 | United States |